179
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE “MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
COMPARATIVE ANALYSIS OF GLUCOCORTICOID PRICES IN THE
TREATMENT OF RHEUMATOID ARTHRITIS
Sey niyazo a B.M.
Suyuno N.D.
Tashken Pha maceu ical Ins i u e, Tashken ci y, Republic o Uzbekis an
e-mail: [email p o ec ed]
h ps://doi.o g/10.5281/zenodo.17332518
Rele ance: heuma oid a h i is is a ch onic au oimmune disease o connec i e issue,
cha ac e ized by p og essi e join damage and de o mi y, as well as he de elopmen o disabili y.
Con empo a y pha maco he apy includes disease-modi ying an heuma ic d ugs, biological agen s,
and symp oma ic ea men . Glucoco icoids a e adminis e ed in combina ion wi h o he he apeu ic
agen s and play an impo an ole in con olling he in lamma o y p ocess and managing disease
exace ba ions. In e na ional and na ional clinical guidelines con i m hei e icacy and widesp ead
applica ion, which highligh s he ele ance o analyzing he a ailabili y o hese medica ions.
Pu pose o he s udy: is o conduc a compa a i e analysis o he p ices o p ednisolone and
me hylp ednisolone ecommended in he na ional clinical p o ocol o he ea men o heuma oid
a h i is.
Ma e ials and me hods: he s udy u ilized da a om he "Fa m Po al" ("Re e ence P ice Lis ")
as o Sep embe 14, 2025. A compa a i e analysis was pe o med on he e ail p ices o p ednisolone
and me hylp ednisolone pha maceu ical p oduc s, ca ego ized by in e na ional non-p op ie a y
names and b and names, wi h conside a ion o dosage o ms and manu ac u e s.
Resul s: he analysis e ealed ha he ange o p ednisolone and me hylp ednisolone
medica ions is ep esen ed by mul iple b and names p oduced by di e en manu ac u e s.
№
In e na ion
al non-
p op ie y
name
B and names
Manu ac u e
Re ail
p ice,
UZS
Coun y o
o igin
1
P ednisolon
e
P ednisolone -RG 30
mg/ml, 1 ml, № 5
(1x5)
Remedy G oup
JV L d.
23,184
Uzbekis an
2
P ednisolone 30
mg/ml 1 ml, № 10
Radiks L d.
34,003.2
Uzbekis an
3
P ednisolone -RG 30
mg/ml, 1 ml , №10
(2x5)
Remedy G oup
JV L d.
30,912
Uzbekis an
4
P ednisolone 30
mg/ml 1 ml, № 10
(2x5)
Ella a L d.
29,951.1
4
Russia
5
P ednisolone 30
mg/ml 1 ml, № 5
(1x5)
Uzge med Pha m
JV L d.
33,120
Uzbekis an
6
P ednisolone SD 5
mg, № 50 (5x10)
Sha q Da mon
L d.
29,566.5
Uzbekis an
180
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE “MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
7
P ednisolone 5 mg, №
40 (2x20)
JSC Vinh phuc
pha maceu ical
41,659.6
1
Vie nam
8
P ednisolone-
Da ny sia 5 mg, № 40
(4x10)
P JSC Da ny sia
34,211.5
7
Uk aine
9
P ednisolone 5 mg, №
100 (10x10)
Co.l d. Shandong
Xie Kang ai
Pha maceu ical
35,671.4
8
China
10
P ednisolone 30
mg/ml 1 ml, № 3
(3x1)
Agio
Pha maceu icals
L d.
18,006.1
India
11
P ednisolone 5 mg, №
100 (10x10)
Abu aihan
Pha maceu ical
Co.
54,282.0
3
I an
12
Me hylp ed
nisolone
Solu-Med ol 500 mg
P ize
Manu ac u ing
Belgium NV
272,189.
92
Belgium
13
Solu-Med ol 1000 mg
P ize
Manu ac u ing
Belgium NV
571,385.
76
Belgium
14
A imed ol 4 mg, №
30 (3x10)
A an ika Medex
P . L d.
112,690.
57
India
15
A imed ol 16 mg, №
30 (3x10)
A an ika Medex
P . L d.
270,457.
37
India
16
Slide on 4 mg, № 20
(2x10)
AD
Balkanpha ma-
Razg ad
89,931.0
4
Bulga ia
17
Slide on 16 mg, № 20
(2x10)
AD
Balkanpha ma-
Razg ad
213,975.
24
Bulga ia
18
Slide on 500 mg
LTD Uni ed
Bio ech (P)
134,363.
7
India
The ange o p ednisolone medica ions is ep esen ed by di e en o mula ions: ampoules (30
mg/ml) p iced om 18,006.1 o 34,003.2 UZS, and able s (5 mg) p iced om 29,566.5 o 54,282.03
UZS. The ange o me hylp ednisolone medica ions includes in a enous o mula ions (500-1000
mg) p iced om 134,363.7 o 571,385.76 UZS, and able s (4-16 mg) p iced om 89,931.04 o
270,457.37 UZS. These indings indica e ha me hylp ednisolone cons i u es a signi ican ly mo e
expensi e he apeu ic op ion compa ed o p ednisolone, wi h he g ea es cos di e ence obse ed
o injec ions.
Conclusions: he compa a i e analysis demons a ed ha me hylp ednisolone pha maceu ical
p oduc s a e, on a e age, 3-10 imes mo e expensi e han p ednisolone, which may subs an ially
educe hei accessibili y o pa ien s. Fu he mo e, he p ice a ia ion wi hin each d ug g oup eaches
181
Volume 5, Issue 10: Special Issue
(EJAR)
ISSN: 2181-2020
MPHAPP
THE 6TH INTERNATIONAL SCIENTIFIC AND PRACTICAL
CONFERENCE “MODERN PHARMACEUTICS: ACTUAL
PROBLEMS AND PROSPECTS”
TASHKENT, OCTOBER 17, 2025
in-academy.uz
up o wo old, indica ing conside able ma ke he e ogenei y. These indings unde sco e he necessi y
o inco po a ing p ice conside a ions in o s a egies o ensu ing equi able access o essen ial
medicines. They also emphasize he impo ance o a ional d ug selec ion wi hin clinical p o ocols
and he po en ial need o policy measu es aimed a imp o ing a o dabili y and op imizing esou ce
alloca ion in heal hca e sys ems.
